This case is consistent with the mature PDC proliferations associated with myeloid neoplasms, including, but not limited to, myelodysplastic and myeloproliferative disorders such as CMML. This mature PDC proliferation should be distinguished from the blastic PDC neoplasm recognized by the 2008 World Health Organization classification. The constellation of ample cytoplasm, low nuclear-to-cytoplasmic ratio, absence of CD56, and extremely low proliferation index distinguishes the mature PDC proliferation from the aggressive blastic PDC neoplasm.
